Prognostic and Therapeutic Potential of Nuclear Receptors in Head and Neck Squamous Cell Carcinomas
Table 2
Overview of current clinical trials in the field of HNSCC targeting NRs. The NCI protocol ID is given in bold (for further details see: http://www.cancer.gov/CLINICALTRIALS).
NR
Clinical trial / identifier
Drug
Tumor entity
Phase
PPAR
Pioglitazone in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia/NCT00099021
Pioglitazone
Head and Neck Cancer Precancerous/Nonmalignant Condition
Phase II ongoing
Rosiglitazone in Preventing Oral Cancer in Patients With Oral Leukoplakia/NCT00369174
Rosiglitazone
Head and Neck Cancer Precancerous/Nonmalignant Condition
Phase II completed
RAR
Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma/NCT00201279
13-cis Retinoic acid
Oral Cavity Squamous Cell Carcinoma
Phase III completed
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer/NCT00002506
Isotretinoin (combined with Interferon a)
Head and Neck Cancer Esophageal Cancer
Phase II ongoing
Isotretinoin, Interferon Alpha, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer/NCT00054561
Isotretinoin (combined with Interferon a and Vitamin E)
Head and Neck Cancer
Phase III completed
ER
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors/NCT00002608
Tamoxifen (combined with Cisplatin and Doxorubicin)
